Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 30% ± 13% | |
brain | 17 studies | 32% ± 18% | |
eye | 9 studies | 33% ± 15% | |
kidney | 8 studies | 27% ± 10% | |
intestine | 7 studies | 35% ± 17% | |
liver | 7 studies | 29% ± 19% | |
heart | 5 studies | 19% ± 5% | |
uterus | 5 studies | 44% ± 16% | |
prostate | 5 studies | 41% ± 17% | |
pancreas | 4 studies | 64% ± 18% | |
lymph node | 4 studies | 24% ± 9% | |
breast | 4 studies | 36% ± 9% | |
peripheral blood | 3 studies | 23% ± 5% | |
placenta | 3 studies | 72% ± 13% | |
adipose | 3 studies | 34% ± 23% | |
adrenal gland | 3 studies | 20% ± 3% | |
esophagus | 3 studies | 41% ± 30% | |
skin | 3 studies | 32% ± 10% | |
thymus | 3 studies | 39% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 16130.48 | 258 / 258 | 100% | 404.08 | 230 / 230 |
esophagus | 100% | 11384.83 | 1445 / 1445 | 100% | 244.79 | 183 / 183 |
ovary | 100% | 31117.45 | 180 / 180 | 100% | 247.90 | 430 / 430 |
uterus | 100% | 22470.95 | 170 / 170 | 100% | 343.74 | 459 / 459 |
breast | 100% | 11310.14 | 459 / 459 | 100% | 470.40 | 1117 / 1118 |
prostate | 100% | 14328.84 | 245 / 245 | 100% | 284.64 | 501 / 502 |
lung | 100% | 12248.16 | 577 / 578 | 100% | 292.21 | 1154 / 1155 |
stomach | 100% | 8560.69 | 359 / 359 | 100% | 248.10 | 285 / 286 |
bladder | 100% | 14267.29 | 21 / 21 | 100% | 296.90 | 502 / 504 |
brain | 99% | 13129.78 | 2626 / 2642 | 100% | 276.40 | 705 / 705 |
thymus | 100% | 11522.40 | 653 / 653 | 99% | 239.67 | 601 / 605 |
skin | 100% | 13537.41 | 1807 / 1809 | 99% | 300.80 | 469 / 472 |
intestine | 100% | 9341.27 | 966 / 966 | 99% | 267.17 | 523 / 527 |
kidney | 100% | 8990.39 | 89 / 89 | 99% | 200.07 | 894 / 901 |
pancreas | 100% | 6883.16 | 328 / 328 | 99% | 240.18 | 176 / 178 |
liver | 100% | 9840.25 | 226 / 226 | 99% | 190.04 | 400 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 120.09 | 29 / 29 |
muscle | 100% | 9265.96 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7984.24 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 243.77 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 125.95 | 1 / 1 |
blood vessel | 100% | 16847.86 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 10795.05 | 1203 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 167.01 | 78 / 80 |
heart | 95% | 7718.07 | 821 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 48% | 3305.43 | 444 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006325 | Biological process | chromatin organization |
GO_0006281 | Biological process | DNA repair |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_2000779 | Biological process | regulation of double-strand break repair |
GO_0051726 | Biological process | regulation of cell cycle |
GO_1905168 | Biological process | positive regulation of double-strand break repair via homologous recombination |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005886 | Cellular component | plasma membrane |
GO_0000786 | Cellular component | nucleosome |
GO_0035267 | Cellular component | NuA4 histone acetyltransferase complex |
GO_0005515 | Molecular function | protein binding |
Gene name | MORF4L2 |
Protein name | Mortality factor 4-like protein 2 (MORF-related gene X protein) (Protein MSL3-2) (Transcription factor-like protein MRGX) Mortality factor 4-like protein 2 Mortality factor 4 like 2 |
Synonyms | KIAA0026 MRGX |
Description | FUNCTION: Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histone H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. NuA4 may also play a direct role in DNA repair when directly recruited to sites of DNA damage. Also a component of the MSIN3A complex which acts to repress transcription by deacetylation of nucleosomal histones. FUNCTION: Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histone H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. NuA4 may also play a direct role in DNA repair when directly recruited to sites of DNA damage. Also a component of the MSIN3A complex which acts to repress transcription by deacetylation of nucleosomal histones. . FUNCTION: Component of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histone H4 and H2A. This modification may both alter nucleosome - DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. The NuA4 complex ATPase and helicase activities seem to be, at least in part, contributed by the association of RUVBL1 and RUVBL2 with EP400. NuA4 may also play a direct role in DNA repair when directly recruited to sites of DNA damage. Also a component of the MSIN3A complex which acts to repress transcription by deacetylation of nucleosomal histones. . |
Accessions | ENST00000441076.7 ENST00000360458.5 ENST00000451301.5 Q5JXX1 ENST00000442614.5 ENST00000433176.6 Q15014 ENST00000418819.5 ENST00000434230.5 ENST00000422355.5 Q5JXX2 Q5JXX6 |